Biomerica’s inFoods IBS test, a personalized dietary therapy for Irritable Bowel Syndrome (IBS), demonstrated statistically significant improvement in patient symptoms, particularly abdominal pain and bloating, in a recent clinical trial published in •Gastroenterology•. The randomized, multicenter, double-blind, placebo-controlled trial involved 238 patients across eight U.S. academic centers, including Mayo Clinic, Cleveland Clinic, and the University of Michigan. The study highlighted the efficacy of the inFoods IBS test, especially for IBS-M patients, a subgroup with no current FDA-approved drug treatments.
This positive clinical data represents a potential paradigm shift in IBS management. The inFoods IBS test offers a non-pharmaceutical approach to alleviate symptoms, addressing a significant unmet need for IBS-M patients, who comprise about 33% of the IBS market. This personalized approach contrasts with traditional, less effective methods and suggests a move toward precision nutrition in gastroenterology. The study’s publication in a high-impact journal like •Gastroenterology• lends significant credibility to this approach.
The trial revealed that 59.6% of patients using the inFoods IBS test achieved the FDA responder definition for abdominal pain reduction compared to 42.2% in the control group. Furthermore, 67.1% of IBS-C patients and 66.0% of IBS-M patients in the treatment group met this benchmark, compared to 35.8% and 29.5% in their respective control groups. The inFoods IBS test works by measuring a patient’s immune response to a panel of foods and identifying specific triggers to eliminate from their diet. This targeted method differentiates it from traditional IgG food tests, offering a clinically validated approach to personalized dietary management for IBS.
This successful clinical trial and subsequent publication mark a significant advancement in IBS treatment. The data supports the potential for widespread adoption of the inFoods IBS test, offering a much-needed non-drug therapeutic option. This could lead to improved patient outcomes, reduced healthcare costs, and further development of personalized dietary interventions for other gastrointestinal disorders. This development also strengthens Biomerica’s position in the diagnostic-guided therapy market, potentially paving the way for similar tests and therapies in the future.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
